1 **Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time**

2 Lauren E. Gentles^{a,b}, Leanne Kehoe^c, Katharine H.D. Crawford^{a,d,e}, Kirsten Lacombe^c, Jane
3 Dickerson^{c,f}, Caitlin Wolf^g, Joanna Yuan^c, Susanna Schuler^c, John T. Watson^h, Sankan
4 Nyanseor^h, Melissa Briggs-Hagen^h, Sharon Saydah^h, Claire M. Midgley^h, Kimberly Pringle^h,
5 Helen Chu^g, Jesse D. Bloom^{a,d,i,#}, and Janet A. Englund^{c,j#}

6 ^aDivision of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer
7 Research Center, Seattle, Washington, USA

8 ^bDepartment of Microbiology, University of Washington, Seattle, Washington, USA

9 ^cDivision of Infectious Disease, Seattle Children's Hospital, Seattle, Washington, USA

10 ^dDepartment of Genome Sciences, University of Washington, Seattle, Washington, USA

11 ^eMedical Scientist Training Program, University of Washington, Seattle, Washington, USA

12 ^fDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle,
13 Washington, USA

14 ^gDivision of Allergy and Infectious Diseases, University of Washington, Seattle, Washington,
15 USA

16 ^hDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

17 ⁱHoward Hughes Medical Institute, Seattle, Washington, USA

18 ^jDepartment of Pediatrics, University of Washington, Seattle, Washington, USA

19 Running head: Longitudinal SAR-CoV-2 antibody dynamics in children

- 20 # Address correspondence to Jesse D. Bloom, jbloom@fredhutch.org, or Janet A. Englund,
- 21 janet.englund@seattlechildrens.org.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicits an antibody response that targets several viral proteins including spike (S) and nucleocapsid (N); S is the major target of neutralizing antibodies. Here, we assess levels of anti-N binding antibodies and anti-S neutralizing antibodies in unvaccinated children compared with unvaccinated older adults following infection. Specifically, we examine neutralization and anti-N binding by sera collected up to 52 weeks following SARS-CoV-2 infection in children and compare these to a cohort of adults, including older adults, most of whom had mild infections that did not require hospitalization. Neutralizing antibody titers were lower in children than adults early after infection, but by 6 months titers were similar between age groups. The neutralizing activity of the children's sera decreased modestly from one to six months; a pattern that was not significantly different from that observed in adults. However, infection of children induced much lower levels of anti-N antibodies than in adults, and levels of these anti-N antibodies decreased more rapidly in children than in adults, including older adults. These results highlight age-related differences in the antibody responses to SARS-CoV-2 proteins and, as vaccines for children are introduced, may provide comparator data for the longevity of infection-elicited and vaccination-induced neutralizing antibody responses.

Keywords

SARS-CoV-2, pediatric serology, neutralizing antibodies, anti-nucleocapsid antibodies, longitudinal dynamics

Introduction

SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), elicits an antibody response targeting multiple viral proteins following infection. Anti-spike (S) antibodies are of particular importance because S is the major target of neutralizing antibodies and neutralizing anti-S antibody titers correlate with protection (1–4). For this reason, currently authorized vaccines only include the S antigen and specifically induce anti-S responses. Additionally, SARS-CoV-2 neutralization assays are designed to measure the potency of antibodies that block viral binding and entry to cells, including via inhibiting S binding to host angiotensin converting enzyme 2 (ACE2) receptor on host cells, and/or inhibiting S fusion. Nucleocapsid (N) protein is also highly immunogenic during SARS-CoV-2 infection and is a predominant target of binding antibodies making it a robust marker of infection. In adults, circulating antibodies rise to peak titers within 3-5 weeks after infection and then gradually begin to wane (1, 3, 5–14). Studies have shown a strong positive correlation between neutralizing antibody titers and protection from subsequent infection (4, 15–19).

COVID-19 in children tends to be milder than in adults, resulting in lower risk of progression to hospitalization and death (20, 21). However, clinical manifestations of COVID-19 vary widely in children as in adults and can range from asymptomatic infections to illness lasting for several months (22). Furthermore, infection by SARS-CoV-2 in children causes a greater burden of hospitalization and death than the pre-vaccine burden of some common childhood illnesses, including varicella (23). Previous work has documented the acute and convalescent dynamics of the SARS-CoV-2 antibody response in adults across a wide range of ages and disease severities

(1, 3, 8, 10, 11, 14, 23, 24), but fewer data are available detailing the longevity of circulating antibodies in the pediatric population (24–27).

Here, we follow a cohort of 32 SARS-CoV-2-infected convalescent children <18 years old for up to 52 weeks post-symptom onset, measuring anti-S neutralizing antibody levels with a pseudoneutralization assay, and anti-N binding antibody levels. We compare the pediatric antibody response to those in a previously characterized cohort of adults (3).

Materials and Methods:

Pediatric Participants

Our IRB-approved study enabled us to enroll children, defined as <18 years old at enrollment, including children with underlying medical conditions, and obtain sera for the assessment of immune responses to SARS-CoV-2 infection at Seattle Children’s Hospital, Seattle, WA, beginning in April 2020. Informed consent was obtained from parents and assent from children over 7 years of age. The REDCap electronic data collection tool was used to acquire demographics, hospitalization data; clinical information including respiratory support, ICU admission, length of stay; laboratory studies including viral testing results, and medical history including chronic underlying medical conditions (28). This study was reviewed and approved by the Seattle Children’s Hospital IRB[§].

Children with confirmed or presumed SARS-CoV-2 infection were recruited to our study during April 2020 through January 2021. Children were considered to have a confirmed SARS-CoV-2 infection if they tested positive for SARS-CoV-2 by RT-PCR. Children were presumed to have SARS-CoV-2 infection if they did not have documentation of a positive RT-PCR, but had detectable SARS-CoV-2-specific antibodies and either: 1) presented with confirmed Multisystem

Inflammatory Syndrome in Children (MIS-C), or 2) were symptomatic and had an RT-PCR-positive household contact. Reported symptoms included but were not limited to sore throat, cough, fever, loss of taste or smell, fatigue, runny nose, head ache, and diarrhea.

Enrollment included hospitalized children, children who were tested for SARS-CoV-2 using RT-PCR as outpatients as determined by their provider, and children who did not receive medical care but were recruited from the community, including community-based surveillance platforms (29). Children were recruited during acute illness with sera drawn at approximately 4-8 weeks (1-2 months), 24 weeks (6 months), and 52 weeks (12 months) following symptom onset for confirmed or presumed infection. Only children who provided at least two specimens by May 2021 were included in this analysis. In addition, only presumed cases with at least one positive serological result were included (**Supplemental Table 1**). For asymptomatic cases, weeks post-positive RT-PCR test result was used as a substitute for weeks post-symptom onset. For children who developed MIS-C, “weeks post-symptom onset” refers to acute infection symptoms before MIS-C onset. No children in this study were vaccinated prior to specimen collection.

Adult Participants

Adult specimens were collected as a part of the Hospitalized or Ambulatory Adults with Respiratory Viral Infections (HAARVI) cohort at the University of Washington Department of Medicine (3, 30, 31). Adults were enrolled from March through May of 2020. A convenience sample of adults who provided specimens at roughly eight- and twenty-four-weeks post-symptom onset were included in this analysis. Study enrollment and specimen collection are detailed elsewhere (3, 30, 31). Briefly, adults were enrolled in the study following RT-PCR confirmed SARS-CoV-2 infection. Inpatients were recruited for enrollment during their hospital

stay at Harborview Medical Hospital, University of Washington Medical Center, or Northwest Hospital in Seattle, Washington in 2020. Asymptomatic adults were identified as participants who responded “None” to a symptom questionnaire and tested positive for SARS-CoV-2 infection via outpatient or community testing. Informed consent was provided by all participants or their legally authorized representatives. No adults in this study were vaccinated prior to specimen collections since no vaccines were available during the collection period, and no adults in this study were enrolled in ongoing vaccine clinical trials. Weeks post-positive RT-PCR test result was used in lieu of weeks post-symptom onset for asymptomatic adults.

Laboratory Methods

Pediatric specimen collection

Whole blood collection was scheduled for 4 to 8-weeks, 24-weeks, and 52-weeks post-symptom onset for the pediatric cohort (**Supplemental figure 1**). Blood specimens were collected in serum separator tubes, stored at 5°C, and spun within 24 hours before being aliquoted and stored at -80°C. Heat inactivation of all specimens was performed at 56°C for 30 minutes before performing serological assays.

Adult specimen collection

Whole blood collection was scheduled for 8- and 24-weeks post-symptom onset for the adult cohort. Blood specimens were immediately added to acid citrate dextrose tubes upon collection which were then spun down to separate out the red blood cell fraction. Within 6 hours following collection, aliquots of these specimens were frozen at -20°C for storage. Prior to use in serological assays, all specimens were heat inactivated at 56°C for one hour.

Neutralization assays

Neutralization assays were performed as previously reported using spike-pseudotyped lentiviral particles (3). The spike protein used is based on Wuhan-Hu-1 (GenBank: [MN908947](#)) with a 21 base pair deletion (delta21) at the terminus of the cytoplasmic tail that enhances viral titers (32–37). The spike also contains the mutation D614G that has become predominant in circulating strains (38). Plasmid HDM_Spikedelta21_D614G encoding this spike protein is available from AddGene (no. 155130) or BEI Resources (NR-53765) along with the full annotated sequence. To perform neutralization assays, 1.25×10^4 HEK-293T-ACE2 cells (39) (BEI resources NR-52511) are added in 50ul per well of a 96-well poly-L-lysine coated plate (Greiner; no. 655936). Our limit of detection for the neutralization assay is 1:20 since this is the starting serum dilution. All assays included pre-pandemic pooled serum collected between 2015 to 2018 as a negative control. No substantial neutralization was observed for a pool of pre-pandemic sera at a dilution of 1:20. SARS2 Spike-D614G-delta21 pseudotyped lentivirus particles encoding luciferase were added at a dilution of 200,000 RLU per well as determined by titering. The virus-antibody plate was then incubated for 1 hour at 37°C before being added to the plate with cells. Neutralization titers were determined using a plate reader to measure luciferase activity at 50 hours post-infection. Measurements were given as the reciprocal dilution of sera at which viral infection was inhibited by 50% (NT_{50}). NT_{50} values were calculated using the neutcurve python package version 0.5.3 available here: <https://github.com/jbloomlab/neutcurve> which fit a Hill curve to our data to determine the 50% inhibitory concentration (IC_{50}). NT_{50} values reported here were the reciprocal of the IC_{50} .

SARS-CoV-2 IgG assay

The SARS-CoV-2 IgG assay, an FDA Emergency Use Authorized immunoassay, which utilizes a chemiluminescent test to assess immunoglobulin G (IgG) binding to nucleocapsid (N) protein, was performed according to manufacturer specifications (Abbott). Anti-N IgG index values were assessed; higher index values reflected higher antibody levels. An index value of > 1.40 is considered a positive result for this assay. Sensitivity and specificity of the SARS-CoV-2 IgG assay have been reported elsewhere (23, 40–44).

Comparison of antibody levels in a subset of immunocompetent children and adults

For comparison of antibody levels between pediatric participants and adults, we limited our analysis to only specimens that were collected within a similar range of weeks post-onset between 8-13 (first collection period) and 24-29 (second collection period) weeks for both cohorts. In this sub-analysis, we excluded participants with MIS-C development, complicating immunocompromising conditions, or receipt of multiple blood transfusions. We assessed changes in antibody titers over time among a limited number of children and adults with two specimens collected within these comparative time frames. Statistical significance was determined by Mann Whitney test.

Results

Study participants. From April 2020 through June 2021, we enrolled 97 pediatric participants of whom 42 had completed at least 6-months of follow-up with two blood draws obtained by May 2021 (**Figure 1**). Thirty-two of the 42 children had evidence of confirmed or presumed infection and were included in the pediatric analysis: 27 of 32 had a confirmed positive RT-PCR

test, including one of two children who presented with MIS-C; one of 32 had a positive serological test result and presented with MIS-C; and four of 32 had a positive serological test result and a known RT-PCR-positive household member (**Supplemental Table 1**). Among the 32 children included in this analysis, median age was 12 years, 6 (19%) were female, 5 (16%) were symptomatic and hospitalized, 25 (78%) were symptomatic but not hospitalized, and 2 (6%) were asymptomatic during acute infection (**Table 1, Figure 2**). Of the two children who developed MIS-C: one (C27) had an asymptomatic acute infection (identified through RT-PCR) and subsequently required ICU admission and supplemental oxygen in the form of bilevel positive airway pressure upon the onset of MIS-C symptoms; the other (C15) had an initial SARS-CoV-2 respiratory infection managed as an outpatient but was subsequently hospitalized with MIS-C, during which time C15 was SARS-CoV-2 RNA-negative and antibody-positive. Five children had underlying immunocompromising conditions or received multiple blood transfusions; four of whom were hospitalized. Among the 25 children who were not immunocompromised, did not receive multiple blood transfusions, and did not present with MIS-C (**Figure 2A**), one child was hospitalized, 22 children were symptomatic but not hospitalized, and two children were asymptomatic.

A second cohort of 14 SARS-CoV-2-infected unvaccinated immunocompetent adults between the ages of 47 and 79 years (median: 65) was included in this study as a comparator group. We previously profiled neutralizing antibody dynamics for all these adults out to 90 days post-symptom onset (3) (See **Supplemental Table 2**). Here we performed additional assays for the same adult participants to enable direct comparison with the pediatric cohort in a sub-analysis. This convenience sample of 14 adults included two who were symptomatic and hospitalized, 8 who were symptomatic non-hospitalized, and 4 who were asymptomatic. Eight (57%) adults

were female. Two adult participants reported underlying conditions: one participant (A3) was recorded as having diabetes, chronic obstructive pulmonary disease, asthma, and obstructive sleep apnea; and another (A13) had hypertension.

Specimen collection. During the 4- and 24-week pediatric blood collections, specimens were collected from the 32 children at a median of 4.5 weeks (IQR: 2.5weeks; range: 2-18weeks) and 26 weeks (IQR: 1.25weeks; range: 23-35weeks), respectively; 3 children also had blood collected at 52 weeks. At 8- and 24-weeks, specimens were collected from the 14 adults at a median of 9.5 (range: 8-13weeks, IQR:1wk) and 25 weeks (range: 24-29weeks, IQR: 1wk), respectively. To compare pediatric and adult responses, we performed a sub-analysis which included specimens collected within two collection periods: the first at 8-13 weeks, and the second at 24-29 weeks. This sub-analysis included specimens from all 14 adults; for children, 7 children had blood drawn in the first collection period (median = 9.5 weeks; IQR = 2.5) and 24 children had blood drawn in the second collection period (median 26 weeks; IQR=1). Five children and 14 adults, with specimens collected at both timepoints, were included in fold-change analyses.

Neutralization dynamics over time in children. We measured neutralization titers for the pediatric specimens collected at each time period (**Figure 2A, B, & C**). All children with confirmed or presumed infections had measurable neutralizing antibody titers for at least one specimen. For the 25 children without MIS-C or immunocompromising conditions or multiple blood transfusions, overall neutralization titers changed very little over the course of 24 weeks from a geometric mean NT₅₀ of 214 and 244 for the first and second collection period, respectively. Interestingly, a greater than 4-fold increase in neutralization titer between the first

and second collection period was seen for four children all of whom were symptomatic but not hospitalized. If these four children are excluded, the geometric mean NT₅₀ decreases by 1.86-fold from the first to the second collection period (from 245 to 132, respectively). For two of the 25 children without immunocompromising conditions, a decrease of greater than 4-fold between 4 and 24 weeks was observed. Both children were symptomatic of whom one was hospitalized. For 19 (76%) of the 25 children, less than 4-fold (range 3.86- to 1.02-fold) changes in neutralization titers were observed. One child with increasing titers, (C32), had no detectable neutralization titer at 3 weeks post-symptom onset despite testing positive by RT-PCR, but subsequently developed high neutralization titers by 26 weeks. Despite the variability among individual immunocompetent children, some trends in the overall antibody dynamics were observed (**Figure 3A**). Nearly all immunocompetent children had neutralizing activity at all timepoints, and the majority of children (15 out of the 25 total) exhibited at least a 25% decrease in neutralization titers over 24 weeks.

For further clinical and laboratory data on children with underlying immunocompromising conditions, multiple blood transfusions, or MIS-C, please refer to Figures 2B & C. Three children with specimens at 52 weeks had detectable neutralizing antibodies (**Figure 2A, B, & C**). Of note, one child (C26) with blood collected at 52 weeks reported a febrile illness, with negative SARS-CoV-2 RT-PCR, between the 24- and 52- week specimen collection (**Figure 2C**).

Comparison of neutralization dynamics in immunocompetent children and older adults.

We next compared neutralization titers and their longitudinal dynamics in children and adults. To accomplish this, we measured plasma neutralizing antibody levels from adults over a 24-week

period. Neutralization titers for specimens collected at 8- to 13-weeks post-symptom onset (first collection period) were previously reported using the same spike pseudotyped lentivirus neutralization assay but without the D614G spike mutation (3). Here, we repeated the neutralization assays using spike pseudotyped lentivirus encoding D614G as well as performing neutralization assays for the first time on specimens collected between 24 and 29 weeks (second collection period). Neutralization titers had a geometric mean of 385 (range: 56 - 4,487) and 302 (range: 67 – 880) at the first and second collection period, respectively (**Supplemental figure 2**). Of the 14 participants in our adult cohort, only one demonstrated a greater than 4-fold decrease in neutralization titer over the observation period, and no adults showed an increase greater than 4-fold. There were no adults for whom neutralization titers fell below the limit of detection during the timeframe tested.

For comparison of neutralization titers between the children and adults including older adults, we restricted our analysis to only specimens collected in the same timeframe for both cohorts, as well as only including children without immunocompromising conditions, those who did not receive multiple blood transfusions, and those without MIS-C. In this sub-analysis, we found that children had significantly lower neutralization potency (geometric mean titer [GMT] = 118, range: 46-256, N=7, $p<0.05$) than adults (GMT = 385, range: 56-4,487, N=14) during the first collection period, but titers were not significantly different between age groups by the second collection period (children: GMT= 244, range: 27-13,694, N=22; adults: GMT = 302, range: 67-880, N=14; $p = 0.23$) (**Figure 3B**). If the four children with neutralization titers that increased by greater than 4-fold are excluded, the children's GMT for the second collection period is 2.46-fold lower than the adults' (123 compared to 302 in children and adults, respectively). We calculated the fold change in titers for each individual measured at the first collection period relative to

those measured for the same individual during the second time period. Fold change analysis was limited to 5 children with specimens collected at both first and second collection period; no difference in the fold change between children (geometric mean fold decrease = 1.12, N=6,) and adults (geometric mean fold decrease = 1.28, N=14) was detectable ($p = 0.893$). (**Figure 3C**).

Anti-nucleocapsid antibody dynamics over time in children. Anti-N antibody levels were determined for all pediatric specimens (**Figure 4A, B, & C**). Among the 25 children without immunocompromising conditions, multiple blood transfusions, or MIS-C, 23 and 14 had detectable anti-N antibodies at the first and second collection periods, respectively; 2 children with confirmed infection by RT-PCR (C1 and C32) did not have detected anti-N antibodies at either timepoint. Anti-N antibody levels dropped considerably from a geometric mean index of 3.7 to 1.3 over 24 weeks. Eighteen of the 23 children, who were positive for anti-N antibodies at the first collection period, exhibited a decrease in index values of greater than 2-fold, and an additional five changed less than 2-fold. No children showed an increase in anti-N antibodies. In totality, the children without immunocompromising conditions showed very similar declining trends in anti-N antibody levels across time (**Figure 5A**). Of the children with a positive index at 4 weeks, values ranged from 1.9 to 8.0 and from undetectable to 7.3 by the first and second collection periods, respectively.

For anti-N antibody levels and clinical information for the children with underlying immunocompromising conditions, multiple blood transfusions, or MIS-C refer to Figure 4B & C. The antibody dynamics out to 52-weeks post-symptom onset were measured for three children all of whom had levels below the limit of detection by this later time period (**Figure 4A, B, & C**).

Comparison of pediatric and adult anti-nucleocapsid antibody dynamics. Next, we compared anti-N antibody dynamics in children and adults. We first measured anti-N antibody levels for all adult specimens in our cohort (**Supplemental figure 3**). Overall, geometric mean values in adults fell from 6.0 to 3.3 between the first and second collection period, respectively. One adult (A12) had values below the limit of detection at both 8- and 24-weeks post-symptom onset. Of the adults with a positive index at 8 weeks, values ranged from 4.2 to 9.4 and from 1.9 to 7.7 by the first and second collection period, respectively. No adults with positive index values at the first timepoint fell below the limit of detection by the later timepoint. This is in stark contrast to the pediatric cohort where many fell below detectable levels over the course of the study. Furthermore, only 3 adults showed a greater than 2-fold decrease in index values.

Compared to the pediatric cohort, adults had higher anti-N antibody levels at both timepoints measured although not quite reaching statistical significance at 8-13 weeks (children: GMT = 4.7, range: 3.0-6.2; adults: GMT = 6.0, range: 0.8-9.4; $p=0.053$) (**Figure 5B**). The difference between adult and child index values was greatest at the later 24- to 29-week timepoint (children: GMT = 1.2, range: 0.2-7.3; adults: GMT = 3.3, range: 0.2-7.7; $p<0.0005$) suggesting that anti-N antibodies may wane faster in children than adults. To test this, we compared the fold change between the first and second collection periods in children and in adults. We found a greater decrease for the pediatric cohort (geometric mean decrease of 4-fold) demonstrating that these children lost N antibody binding at a faster rate than the adult cohort (geometric mean decrease of 1.8-fold) (**Figure 5C**).

Discussion

In this study, we describe the kinetics of serum antibodies over time in children after infection with SARS-CoV-2. In our convenience samples of unvaccinated children and adults with confirmed or presumed SARS-CoV-2 infection, we found that pediatric serum neutralizing titers were maintained over 24 weeks while anti-N-binding antibodies waned quickly. Importantly, neutralizing antibody titers were highly variable among individual children as has been previously observed in adults (1, 3, 6, 8, 10, 11, 23, 24, 45). Other studies have demonstrated that greater disease severity and higher viral load are associated with higher antibody levels in adults (3, 10, 46). The limited number of asymptomatic, hospitalized, and MIS-C cases in our cohort prevented analysis of the role that disease severity may play in this variability. While further investigation is needed, the wide range of neutralization titers and anti-N antibody levels observed in our group of 22 immunocompetent, non-MIS-C presenting children, who were symptomatic but not hospitalized, suggests that disease severity may not entirely explain the observed heterogeneity.

There are several reasons why antibody responses to SARS-CoV-2 infection could be different in children compared to adults, including disease typically being less severe in children (21, 47–51) as well as immune senescence and greater burden of comorbidities in older adults (52–58). Further, primary infections with respiratory pathogens tend to occur early in life leaving uncertainty about how antibody responses to primary infection may differ with age. Additionally, children are susceptible to life threatening MIS-C following infection, and it remains unclear if and/or how the immune response following infection may impact development of such sequelae.

Interestingly, only a modest and non-significant decrease in neutralizing antibody level was detected for pediatric specimens collected out to six months. A similar persistence in

neutralization potency was also observed in the adult cohort, suggesting that there might be long term maintenance of neutralizing antibodies regardless of age following SARS-CoV-2 infection. This finding is in line with several other bodies of work demonstrating the persistence of neutralizing antibodies over many months (9, 26, 59–61). We did, however, detect lower levels of neutralization in children’s serum compared to adults early after infection. This finding is perhaps surprising given recent work, in the context of vaccination, showing that older adults, similar to the age group of adults reported here, develop lower neutralizing titers than younger adults (62). Antibody dynamics across ages may be different between infection and vaccination, and other factors such as specimen collection time or disease severity could also contribute the difference between this study and ours. Interestingly, by 24 weeks, a difference in neutralization titers between children and adults was no longer detectable. This leveling of neutralization titers over time has also been observed for some (3) but not all (11) studies of adults who have disease of different severity: adults with severe disease have higher initial titers at early, but not later, timepoints (3). Overall, the neutralizing antibody kinetics that we observe for children are similar to adults with mild infections (3, 14). A previous study corroborates our findings of lower pediatric neutralization titers early after infection by measuring neutralization titers in children and adults out to 60 days (24), and another study looking at only hospitalized children and adults reported the same (63). However, one study (26) found that younger children had higher titers than older children and adults. Differences in study population and sampling timepoints could explain these differences.

The most striking difference in SARS-CoV-2 antibody levels between children and adults was seen for anti-N antibodies. Although not statistically significant, children tended to have lower levels than adults early after infection and a significantly lower level after six months. Lower

anti-N antibody levels in children than adults have been reported in another study as well (24). Those authors speculated that, since nucleocapsid protein is disseminated during infection through the lysis of infected cells, children may experience lower levels of N antigen expression due to their reduced duration of illness and potentially lower levels of viral replication (24). Alternatively, the cumulative lifetime exposure to betacoronavirus infections in adults may repeatedly boost antibodies to the more conserved nucleocapsid proteins that are cross-reactive to SARS-CoV-2, as has been observed for conserved influenza proteins (64). It is important to note that several studies have found that the SARS-CoV-2 IgG assay used for this study decreases in sensitivity over time faster than in other assays (13, 23, 40–44). In addition, the SARS-CoV-2 IgG assay only has emergency use authorization for qualitative assessment of antibodies and not quantitative.

Limitations of our study include small sample size, a limited number of children with follow-up at 52-weeks, and differences in the sex distribution between the pediatric and adult cohorts. Follow-up is ongoing with children who had not yet reached 52-weeks post-symptom onset at the time of this analysis. Furthermore, blood volume obtained from younger children is limited and therefore the number of assays utilized was also limited. The adult comparative specimens were obtained from the same geographic location and analyzed in the same laboratory, although not necessarily collected from the same families or at the same time. The adult specimens were also plasma, whereas the pediatric specimens were serum, and the differences in collection and storage of these could possibly result in slight differences in antibody concentrations. Additionally, the adults in this study were a convenience sample of a broader study, and approximately half were older adults, over 65 years of age, meaning that the data presented here may not be representative of all adults across wider age ranges. Likewise, our pediatric cohort

was also a convenience sample and may also not be representative of the broader population. Furthermore, unlike the pediatric cohort, adults were only enrolled following RT-PCR confirmed infection without enrollment based on household RT-PCR positive contacts. Of note, both children and adult cohorts were enrolled prior to the widespread introduction of the SARS-CoV-2 Delta variant.

Overall, our results suggest that although neutralizing antibody responses to SARS-CoV-2 are broadly similar between adults and children, anti-N antibodies are elicited at lower levels in children than adults. These results contribute to our knowledge of pediatric immune responses to SARS-CoV-2 over time, and the data on the longevity of neutralizing antibodies may prove valuable for comparison investigations of immunity induced by vaccines in children.

Acknowledgements:

The authors would like to acknowledge Andrea Loes for her supportive role in this study. This work was supported by CDC BAA75D301-20-R-67897 and also by the NIAID/NIH R01AI141707 and R01AI127893 grant to J.D.B. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). In addition, J.D.B. is an Investigator of the Howard Hughes Medical Institute. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. DGE-1762114 to L.E.G. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation. The funders had no role in study design, data collection, or the decision to submit the work for publication.

J.D.B. consults for Moderna, Oncorus, and Flagship Labs 77. J.D.B. is an inventor on Fred Hutch licensed patents related to deep mutational scanning of viral proteins. J.A.E. consults for AstraZeneca, Sanofi Pasteur, Meissa Vaccines, Teva Pharmaceuticals, and receives research support from AstraZeneca, Merck, Novavax, and Pfizer. H.Y.C. receives research support from Gates Ventures, NIH, CDC, DARPA, Sanofi-Pasteur, and Cepheid and serves on the advisory boards for Merck, Pfizer, Ellume, and the Gates Foundation. All other authors report no additional competing interests.

Pediatric study design, patient enrollment and data acquisition, and specimen collection were completed by J.A.E., L.K., K.L., J.Y., and S.S. Adults study design, patient enrollment and data acquisition, and specimen collection was completed by H.Y.C. and L.W. Neutralization assays, data analysis, and manuscript writing were performed by L.E.G. All work was performed under the direction of J.D.B. and J.A.E. SARS-CoV-2 IgG assay were performed by J.D. Manuscript editing and review was completed by J.D.B, J.A.E., H.Y.C., L.K., K.L., S.N., S.S., K.P., M.B.H, and C.M.M.

References:

1. Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, Yang X, Wang B, Chen L, Chen Q, Wu Y, Liu J, Yang X, Li W, Zhu B, Zhou W, Wang H, Li S, Lu S, Liu D, Li H, Krawczyk A, Lu M, Yang D, Deng F, Dittmer U, Trilling M, Zheng X. 2021. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. 1. Nature Communications 12:1813.
2. Shrock E, Fujimura E, Kula T, Timms RT, Lee I-H, Leng Y, Robinson ML, Sie BM, Li MZ, Chen Y, Logue J, Zuiani A, McCulloch D, Lelis FJN, Henson S, Monaco DR, Travers M,

416 Habibi S, Clarke WA, Caturegli P, Laeyendecker O, Piechocka-Trocha A, Li JZ, Khatri A, Chu
 417 HY, Collection & MC-19, Team16[‡] P, Villani A-C, Kays K, Goldberg MB, Hacohen N,
 418 Filbin MR, Yu XG, Walker BD, Wesemann DR, Larman HB, Lederer JA, Elledge SJ. 2020.
 419 Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.
 420 Science 370.

421 3. Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, Shuey K, Casto
 422 AM, Fiala B, Wrenn S, Pettie D, King NP, Greninger AL, Chu HY, Bloom JD. 2020. Dynamics
 423 of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome
 424 Coronavirus 2 Infection. The Journal of Infectious Diseases
 425 <https://doi.org/10.1093/infdis/jiaa618>.

426 4. Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W, Zhou H,
 427 Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal
 428 C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, Laan LWP van der, Hejazi N, Huynh C,
 429 Miller J, Sahly HME, Baden LR, Baron M, Cruz LDL, Gay C, Kalams S, Kelley CF, Kutner M,
 430 Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO,
 431 Koup RA, Assays on behalf of the I, Moderna I, Efficacy (COVE) CVPN
 432 (CoVPN)/Coronavirus, Teams and USG (USG)/CoVPN B. 2021. Immune Correlates Analysis
 433 of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.

434 5. Beaudoin-Bussieres G, Laumaea A, Anand SP, Prevost J, Gasser R, Goyette G,
 435 Medjahed H, Perreault J, Tremblay T, Lewin A, Gokool L, Morrisseau C, Begin P, Tremblay C,
 436 Martel-Laferriere V, Kaufmann DE, Richard J, Bazin R, Finzi A. 2020. Decline of Humoral
 437 Responses against SARS-CoV-2 Spike in Convalescent Individuals. mBio 11.

- 438 6. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, Mills R, Teng E,
439 Kamruzzaman M, Garcia-Beltran WF, Astudillo M, Yang D, Miller TE, Oliver E, Fischinger S,
440 Atyeo C, Iafrate AJ, Calderwood SB, Lauer SA, Yu J, Li Z, Feldman J, Hauser BM, Caradonna
441 TM, Branda JA, Turbett SE, LaRocque RC, Mellon G, Barouch DH, Schmidt AG, Azman AS,
442 Alter G, Ryan ET, Harris JB, Charles RC. 2020. Persistence and decay of human antibody
443 responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.
444 *Sci Immunol* 5:eabe0367.
- 445 7. Wang K, Long Q-X, Deng H-J, Hu J, Gao Q-Z, Zhang G-J, He C-L, Huang L-Y, Hu J-L,
446 Chen J, Tang N, Huang A-L. 2020. Longitudinal Dynamics of the Neutralizing Antibody
447 Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
448 *Clinical Infectious Diseases* <https://doi.org/10.1093/cid/ciaa1143>.
- 449 8. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, Hemmings O, O'Byrne
450 A, Kouphou N, Galao RP, Betancor G, Wilson HD, Signell AW, Winstone H, Kerridge C,
451 Huettner I, Jimenez-Guardeño JM, Lista MJ, Temperton N, Snell LB, Bisnauthsing K, Moore A,
452 Green A, Martinez L, Stokes B, Honey J, Izquierdo-Barras A, Arbane G, Patel A, Tan MKI,
453 O'Connell L, O'Hara G, MacMahon E, Douthwaite S, Nebbia G, Batra R, Martinez-Nunez R,
454 Shankar-Hari M, Edgeworth JD, Neil SJD, Malim MH, Doores KJ. 2020. Longitudinal
455 observation and decline of neutralizing antibody responses in the three months following SARS-
456 CoV-2 infection in humans. 12. *Nature Microbiology* 5:1598–1607.
- 457 9. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M,
458 Meade P, Mendu DR, Muellers K, Stadlbauer D, Stone K, Strohmeier S, Simon V, Aberg J,

- Reich DL, Krammer F, Cordon-Cardo C. 2020. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science* 370:1227–1230.
10. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, Song T, Alshukairi AN, Chen R, Zhang Z, Gan M, Zhu A, Huang Y, Luo L, Mok CKP, Gethamy MMA, Tan H, Li Z, Huang X, Li F, Sun J, Zhang Y, Wen L, Li Y, Chen Z, Zhuang Z, Zhuo J, Chen C, Kuang L, Wang J, Lv H, Jiang Y, Li M, Lin Y, Deng Y, Tang L, Liang J, Huang J, Perlman S, Zhong N, Zhao J, Peiris JSM, Li Y, Zhao J. 2020. Kinetics of viral load and antibody response in relation to COVID-19 severity. *J Clin Invest* 130:5235–5244.
11. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM, Weiskopf D, Sette A, Crotty S. 2021. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* 371.
12. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, Cipolla M, Viant C, Barnes CO, Bram Y, Breton G, Hägglöf T, Mendoza P, Hurley A, Turroja M, Gordon K, Millard KG, Ramos V, Schmidt F, Weisblum Y, Jha D, Tankelevich M, Martinez-Delgado G, Yee J, Patel R, Dizon J, Unson-O'Brien C, Shimeliovich I, Robbiani DF, Zhao Z, Gazumyan A, Schwartz RE, Hatziioannou T, Bjorkman PJ, Mehandru S, Bieniasz PD, Caskey M, Nussenzweig MC. 2021. Evolution of antibody immunity to SARS-CoV-2. *Nature* 591:639–644.
13. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire J, Clearly S, Furrie E, Greig N, Hay G, Templeton K, Lorenzi JCC, Hatziioannou T, Jenks S, Bieniasz PD. 2021. Longitudinal Serological Analysis and Neutralizing Antibody Levels in

- 481 Coronavirus Disease 2019 Convalescent Patients. *The Journal of Infectious Diseases* 223:389–
482 398.
- 483 14. Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan H-X, Lee WS, Wragg KM,
484 Kelly HG, Esterbauer R, Davis SK, Kent HE, Mordant FL, Schlub TE, Gordon DL, Khoury DS,
485 Subbarao K, Cromer D, Gordon TP, Chung AW, Davenport MP, Kent SJ. 2021. Evolution of
486 immune responses to SARS-CoV-2 in mild-moderate COVID-19. *Nat Commun* 12:1162.
- 487 15. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K,
488 Kent SJ, Triccas JA, Davenport MP. 2021. Neutralizing antibody levels are highly predictive of
489 immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*
490 <https://doi.org/10.1038/s41591-021-01377-8>.
- 491 16. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, Tostanoski
492 LH, Yu J, Maliga Z, Nekorchuk M, Busman-Sahay K, Terry M, Wrijil LM, Ducat S, Martinez
493 DR, Atyeo C, Fischinger S, Burke JS, Slein MD, Pessaint L, Ry AV, Greenhouse J, Taylor T,
494 Blade K, Cook A, Finneyfrock B, Brown R, Teow E, Velasco J, Zahn R, Wegmann F, Abbink P,
495 Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kordana N, Li Z, Lifton MA,
496 Mahrokhian SH, Maxfield LF, Nityanandam R, Nkolola JP, Schmidt AG, Miller AD, Baric RS,
497 Alter G, Sorger PK, Estes JD, Andersen H, Lewis MG, Barouch DH. 2020. SARS-CoV-2
498 infection protects against rechallenge in rhesus macaques. *Science* 369:812–817.
- 499 17. Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F,
500 Xiang Z, Yu H, Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao L, Liu
501 X, Wei Q, Qin C. 2020. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus
502 macaques. *Science* 369:818–823.

- 503 18. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Levin
504 EG, Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y, Regev-
505 Yochay G. 2021. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. New
506 England Journal of Medicine 385:1474–1484.
- 507 19. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang M-L, Jerome
508 KR, Bloom JD, Greninger AL. 2020. Neutralizing Antibodies Correlate with Protection from
509 SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. Journal of
510 Clinical Microbiology 58.
- 511 20. Chung E, Chow EJ, Wilcox NC, Burstein R, Brandstetter E, Han PD, Fay K, Pfau B,
512 Adler A, Lacombe K, Lockwood CM, Uyeki TM, Shendure J, Duchin JS, Rieder MJ, Nickerson
513 DA, Boeckh M, Famulare M, Hughes JP, Starita LM, Bedford T, Englund JA, Chu HY. 2021.
514 Comparison of Symptoms and RNA Levels in Children and Adults With SARS-CoV-2 Infection
515 in the Community Setting. JAMA Pediatr <https://doi.org/10.1001/jamapediatrics.2021.2025>.
- 516 21. Li B, Zhang S, Zhang R, Chen X, Wang Y, Zhu C. 2020. Epidemiological and Clinical
517 Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis. Front
518 Pediatr 8:591132.
- 519 22. Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, Murray B, Kläser
520 K, Kerfoot E, Chen L, Deng J, Hu C, Selvachandran S, Read K, Capdevila Pujol J, Hammers A,
521 Spector TD, Ourselin S, Steves CJ, Modat M, Absoud M, Duncan EL. 2021. Illness duration and
522 symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. The Lancet
523 Child & Adolescent Health S235246422100198X.

23. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Donatelli J, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox M-A, Vallari A, Rodgers MA, Prostko J, Hackett J, Trinh L, Wrin T, Petropoulos CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B. 2021. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. *Science Advances* 7:eabh3409.
24. Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin W-H, Wontakal S, Szabo PA, Wells SB, Dogra P, Gray J, Idzikowski E, Stelitano D, Bovier FT, Davis-Porada J, Matsumoto R, Poon MML, Chait M, Mathieu C, Horvat B, Decimo D, Hudson KE, Zotti FD, Bitan ZC, La Carpia F, Ferrara SA, Mace E, Milner J, Moscona A, Hod E, Porotto M, Farber DL. 2021. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. 1. *Nature Immunology* 22:25–31.
25. Roarty C, Tonry C, McFetridge L, Mitchell H, Watson C, Waterfield T, Waxman E, Fairley D, Roew-Setz G, McKenna J, Mallet P, Christy R, Christie K, McManus E, Bennison C, Mullan K, Metryka A, Moore R, Ferris K, Watt A, McGinn C, Foster S, Evans J, Lyttle MD, Ahmad S, Ladhani S, Corr M, Maney J-A, Christie S. 2020. Kinetics and seroprevalence of SARS-CoV-2 antibodies in children. *The Lancet Infectious Diseases* [https://doi.org/10.1016/S1473-3099\(20\)30884-7](https://doi.org/10.1016/S1473-3099(20)30884-7).
26. Bonfante F, Costenaro P, Cantarutti A, Chiara CD, Bortolami A, Petrara MR, Carmona F, Pagliari M, Cosma C, Cozzani S, Mazzetto E, Salvo GD, Dalt LD, Palma P, Barzon L, Corrao G,

546 Terregino C, Padoan A, Plebani M, Rossi AD, Donà D, Giaquinto C. 2021. Mild SARS-CoV-2
547 Infections and Neutralizing Antibody Titers. *Pediatrics* [https://doi.org/10.1542/peds.2021-](https://doi.org/10.1542/peds.2021-052173)
548 052173.

549 27. Dowell AC, Butler MS, Jinks E, Tut G, Lancaster T, Sylla P, Begum J, Pearce H, Taylor
550 GS, Syrimi E, Spalkova E, Davies S, Baawuah F, Beckmann J, Okike I, Ahmad S, Garstang J,
551 Brent AJ, Brent B, Ireland G, Aiano F, Amin-Chowdhury Z, Jones S, Borrow R, Linley E, Poh J,
552 Saliba V, Amirthalingam G, Brown KE, Ramsay ME, Zuo J, Moss P, Ladhani S. 2021. Children
553 develop strong and sustained cross-reactive immune responses against spike protein following
554 SARS-CoV-2 infection. *medRxiv* 2021.04.12.21255275.

555 28. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research
556 electronic data capture (REDCap)--a metadata-driven methodology and workflow process for
557 providing translational research informatics support. *J Biomed Inform* 42:377–381.

558 29. Chu HY, Englund JA, Starita LM, Famulare M, Brandstetter E, Nickerson DA, Rieder
559 MJ, Adler A, Lacombe K, Kim AE, Graham C, Logue J, Wolf CR, Heimonen J, McCulloch DJ,
560 Han PD, Sibley TR, Lee J, Ilcisin M, Fay K, Burstein R, Martin B, Lockwood CM, Thompson
561 M, Lutz B, Jackson M, Hughes JP, Boeckh M, Shendure J, Bedford T, Seattle Flu Study
562 Investigators. 2020. Early Detection of Covid-19 through a Citywide Pandemic Surveillance
563 Platform. *N Engl J Med* 383:185–187.

564 30. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD.
565 2021. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that
566 affect recognition by polyclonal human plasma antibodies. *Cell Host & Microbe* 29:463-476.e6.

31. Garrett ME, Galloway J, Chu HY, Itell HL, Stoddard CI, Wolf CR, Logue JK, McDonald D, Weight H, Matsen FA, Overbaugh J. 2021. High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. *Cell* 184:2927-2938.e11.
32. Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, Bloyet L-M, Zeng Q, Tahan S, Droit L, Ilagan MXG, Tartell MA, Amarasinghe G, Henderson JP, Miersch S, Ustav M, Sidhu S, Virgin HW, Wang D, Ding S, Corti D, Theel ES, Fremont DH, Diamond MS, Whelan SPJ. 2020. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. *Cell Host Microbe* 28:475-485.e5.
33. Dieterle ME, Haslwanter D, Bortz RH, Wirchnianski AS, Lasso G, Vergnolle O, Abbasi SA, Fels JM, Lauder milch E, Florez C, Mengotto A, Kimmel D, Malonis RJ, Georgiev G, Quiroz J, Barnhill J, Pirofski L-A, Daily JP, Dye JM, Lai JR, Herbert AS, Chandran K, Jangra RK. 2020. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. *Cell Host Microbe* 28:486-496.e6.
34. Johnson MC, Lyddon TD, Suarez R, Salcedo B, LePique M, Graham M, Ricana C, Robinson C, Ritter DG. 2020. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. *J Virol* 94:e01062-20.
35. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun* 11:1620.
36. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W-T, Limbo O, Smith C, Song G, Woehl J, Yang L, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren M, Peng L, Ramirez S,

589 Ricketts J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M, Smith DM, Nemazee D, Teijaro JR,
590 Voss JE, Wilson IA, Andrabi R, Briney B, Landais E, Sok D, Jardine JG, Burton DR. 2020.
591 Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small
592 animal model. *Science* 369:956–963.

593 37. Schmidt F, Weisblum Y, Muecksch F, Hoffmann H-H, Michailidis E, Lorenzi JCC,
594 Mendoza P, Rutkowska M, Bednarski E, Gaebler C, Agudelo M, Cho A, Wang Z, Gazumyan A,
595 Cipolla M, Caskey M, Robbiani DF, Nussenzweig MC, Rice CM, Hatziioannou T, Bieniasz PD.
596 2020. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric
597 viruses. *J Exp Med* 217:e20201181.

598 38. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N,
599 Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman
600 TM, de Silva TI, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC,
601 Saphire EO, Montefiori DC, Angyal A, Brown RL, Carrilero L, Green LR, Groves DC, Johnson
602 KJ, Keeley AJ, Lindsey BB, Parsons PJ, Raza M, Rowland-Jones S, Smith N, Tucker RM, Wang
603 D, Wyles MD. 2020. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
604 Infectivity of the COVID-19 Virus. *Cell* 182:812-827.e19.

605 39. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY,
606 Tortorici MA, Veisler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD. 2020. Protocol
607 and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for
608 Neutralization Assays. *Viruses* 12:E513.

40. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC, Greninger AL. 2020. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. *J Clin Microbiol* 58:e00941-20.
41. Padoan A, Bonfante F, Pagliari M, Bortolami A, Negrini D, Zuin S, Bozzato D, Cosma C, Sciacovelli L, Plebani M. 2020. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. *EBioMedicine* 62:103101.
42. Bond KA, Williams E, Nicholson S, Lim S, Johnson D, Cox B, Putland M, Gardiner E, Tippet E, Graham M, Mordant F, Catton M, Lewin SR, Subbarao K, Howden BP, Williamson DA. 2021. Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection. *Pathology* 53:773–779.
43. Favresse J, Eucher C, Elsen M, Gillot C, Van Eeckhoudt S, Dogné J-M, Douxflis J. 2021. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. *3. Microorganisms* 9:556.
44. Theel ES, Johnson PW, Kunze KL, Wu L, Gorsh AP, Granger D, Roforth MM, Jerde CR, Lasho M, Andersen KJ, Murphy BM, Harring J, Lake DF, Svarovsky SA, Senefeld JW, Carter RE, Joyner MJ, Baumann NA, Mills JR. 2021. SARS-CoV-2 Serologic Assays Dependent on Dual-Antigen Binding Demonstrate Diverging Kinetics Relative to Other Antibody Detection Methods. *J Clin Microbiol* 59:e0123121.
45. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan W-H, Chiu SS, Ko RLW, Chan KH, Cheng SMS, Perera RAPM, Cowling BJ, Poon LLM, Peiris M. 2021. Neutralizing antibody titres in SARS-CoV-2 infections. *Nat Commun* 12:63.

631 46. Sun J, Tang X, Bai R, Liang C, Zeng L, Lin H, Yuan R, Zhou P, Huang X, Xiong Q,
632 Peng J, Cui F, Ke B, Su J, Liu Z, Lu J, Tian J, Sun R, Ke C. 2020. The kinetics of viral load and
633 antibodies to SARS-CoV-2. Clin Microbiol Infect 26:1690.e1-1690.e4.

634 47. Wu Z, McGoogan JM. 2020. Characteristics of and Important Lessons From the
635 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314
636 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323:1239–1242.

637 48. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu
638 H, Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K,
639 Xiao H, Xu S, Wong GWK. 2020. SARS-CoV-2 Infection in Children. New England Journal of
640 Medicine 382:1663–1665.

641 49. Bhopal SS, Bagaria J, Olabi B, Bhopal R. 2021. Children and young people remain at
642 low risk of COVID-19 mortality. The Lancet Child & Adolescent Health 5:e12–e13.

643 50. Onder G, Rezza G, Brusaferro S. 2020. Case-Fatality Rate and Characteristics of Patients
644 Dying in Relation to COVID-19 in Italy. JAMA 323:1775–1776.

645 51. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. 2020. Epidemiology of COVID-
646 19 Among Children in China. Pediatrics 145.

647 52. Kudesia P, Salimarouny B, Stanley M, Fortin M, Stewart M, Terry A, Ryan BL. 2021.
648 The incidence of multimorbidity and patterns in accumulation of chronic conditions: A
649 systematic review. J Comorb 11:26335565211032880.

53. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. 2000. Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann N Y Acad Sci* 908:244–254.
54. Palmer DB. 2013. The effect of age on thymic function. *Front Immunol* 4:316.
55. Salam N, Rane S, Das R, Faulkner M, Gund R, Kandpal U, Lewis V, Mattoo H, Prabhu S, Ranganathan V, Durdik J, George A, Rath S, Bal V. 2013. T cell ageing: effects of age on development, survival & function. *Indian J Med Res* 138:595–608.
56. Dugan HL, Henry C, Wilson PC. 2020. Aging and influenza vaccine-induced immunity. *Cell Immunol* 348:103998.
57. Wolff JL, Starfield B, Anderson G. 2002. Prevalence, Expenditures, and Complications of Multiple Chronic Conditions in the Elderly. *Archives of Internal Medicine* 162:2269–2276.
58. Mueller AL, McNamara MS, Sinclair DA. 2020. Why does COVID-19 disproportionately affect older people? *Aging (Albany NY)* 12:9959–9981.
59. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, Li Z, Chao G, Rojas OL, Bang YM, Pu A, Christie-Holmes N, Gervais C, Ceccarelli D, Samavarchi-Tehrani P, Guvenc F, Budylowski P, Li A, Paterson A, Yun YF, Marin LM, Caldwell L, Wrana JL, Colwill K, Sicheri F, Mubareka S, Gray-Owen SD, Drews SJ, Siqueira WL, Barrios-Rodiles M, Ostrowski M, Rini JM, Durocher Y, McGeer AJ, Gommerman JL, Gingras A-C. 2020. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in patients with COVID-19. *Science Immunology* 5.

- 670 60. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, Thompson
671 MR, Bradshaw C, Weinkauff CC, Bime C, Erickson HL, Knox K, Bixby B, Parthasarathy S,
672 Chaudhary S, Natt B, Cristan E, El Aini T, Rischard F, Campion J, Chopra M, Insel M, Sam A,
673 Knepler JL, Capaldi AP, Spier CM, Dake MD, Edwards T, Kaplan ME, Scott SJ, Hypes C,
674 Mosier J, Harris DT, LaFleur BJ, Sprissler R, Nikolich-Žugich J, Bhattacharya D. 2020.
675 Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence
676 Communities and Reveal Durable Humoral Immunity. *Immunity* 53:925-933.e4.
- 677 61. Chia WN, Zhu F, Ong SWX, Young BE, Fong S-W, Bert NL, Tan CW, Tiu C, Zhang J,
678 Tan SY, Pada S, Chan Y-H, Tham CYL, Kunasegaran K, Chen MI-C, Low JGH, Leo Y-S, Renia
679 L, Bertoletti A, Ng LFP, Lye DC, Wang L-F. 2021. Dynamics of SARS-CoV-2 neutralising
680 antibody responses and duration of immunity: a longitudinal study. *The Lancet Microbe* 2:e240–
681 e249.
- 682 62. Brockman MA, Mwimanzi F, Lapointe HR, Sang Y, Agafitei O, Cheung P, Ennis S, Ng
683 K, Basra S, Lim LY, Yaseen F, Young L, Umvilighozo G, Omondi FH, Kalikawe R, Burns L,
684 Brumme CJ, Leung V, Montaner JSG, Holmes D, DeMarco M, Simons J, Pantophlet R, Niikura
685 M, Romney MG, Brumme ZL. 2021. Reduced magnitude and durability of humoral immune
686 responses by COVID-19 mRNA vaccines among older adults.
- 687 63. Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, Garforth SJ,
688 Herrera NG, Jangra RK, Morano NC, Orner E, Sy S, Chandran K, Dziura J, Almo SC, Ring A,
689 Keller MJ, Herold KC, Herold BC. 2020. Immune responses to SARS-CoV-2 infection in
690 hospitalized pediatric and adult patients. *Science Translational Medicine* 12:eabd5487.

64. Jung J, Mundle ST, Ustyugova IV, Horton AP, Boutz DR, Pougatcheva S, Prabakaran P, McDaniel JR, King GR, Park D, Person MD, Ye C, Tan B, Tanno Y, Kim JE, Curtis NC, DiNapoli J, Delagrave S, Ross TM, Ippolito GC, Kleanthous H, Lee J, Georgiou G. 2021. Influenza vaccination in the elderly boosts antibodies against conserved viral proteins and egg-produced glycans. J Clin Invest 131.

Main text tables and figure legends:

Table 1. Pediatric and adult cohort demographics by disease severity.

Pediatric cohort

Characteristic	Asymptomatic n=2	Symptomatic non-hospitalized n=25	Symptomatic hospitalized n=5	Overall n=32
Age, median (range)	10 (9.3-10.7)	11.8 (0.2-17.8)	16 (3.6-17.7)	12 (0.2-17.8)
Sex, no. (%)				
Female	0 (0)	4 (16)	2 (40)	6 (19)
Male	2 (100)	21 (84)	3 (60)	26 (81)
Immunocompromised or received multiple blood transfusions*	0	1	4	5

*No other children reported chronic conditions.

Adult cohort

Characteristic	Asymptomatic n=4	Symptomatic non-hospitalized n=8	Symptomatic hospitalized n=2	Overall n=14
Age, median (range)	69.5 (60-79)	65 (47-76)	59 (54-64)	65 (47-79)
Sex, no. (%)				
Female	3 (75)	4 (50)	1 (50)	8 (57)
Male	1 (25)	4 (50)	1 (50)	6 (43)

699

700 **Figure 1.** *Pediatric study inclusion criteria flowchart.* Evidence of infection included a PCR-
 701 positive test (n=28) or positive serological test result following a known RT-PCR-positive
 702 household exposure (n=4) and/or presentation with MIS-C (n=2).

Figure 2: Neutralization titers in children over time. Neutralizing antibody titers (NT₅₀) in **A**) 25 children with confirmed SARS-CoV-2 infection, **B**) 2 children who developed MIS-C following

acute infection and C) cases complicated by immunosuppression (N = 4) or multiple blood transfusions (N = 1) in 5 children with confirmed SARS-CoV-2 infection followed prospectively over time shown as weeks. Vertical lines represent the week of positive RT-PCR test result(s), and shaded areas indicate weeks with consecutive positive RT-PCR test results. Colors show disease severity during acute infection. Dotted horizontal lines indicate the limit of detection (20).

Figure 3. Neutralization potency kinetics in children compared to adults. A) Aggregated trajectories of pediatric neutralization titers (NT₅₀) longitudinally with lines connecting

716 specimens from the same individual for the 25 pediatric participants without underlying
 717 immunosuppression, receipt of multiple blood transfusions, or MIS-C. **B)** Comparison of adult
 718 and pediatric neutralization titers collected within the time periods 8 to 13 weeks (adults N = 14;
 719 children N = 7) and 24 to 29 weeks (adults N = 14; children N = 22) for the participants without
 720 underlying immunosuppression, receipt of multiple blood transfusions, or MIS-C. **C)** Analysis of
 721 fold change in neutralization titers at 24 to 29 weeks (adults N = 14; children N = 6) relative to
 722 titers at 8 to 13 weeks for adults and children without underlying immunosuppression, receipt of
 723 multiple blood transfusions, or MIS-C. Significance determined by Mann Whitney test.

A

B MIS-C cases

C Cases complicated by immunosuppression or multiple transfusions

Figure 4. Anti-nucleocapsid antibody binding in children over time. Anti-N antibody titers in A)

25 children with confirmed SARS-CoV-2 infection, B) children who developed MIS-C

following acute infection, and C) cases complicated by immunosuppression or multiple blood

transfusions in 5 children with confirmed SARS-CoV-2 infection followed prospectively over time shown as weeks. Vertical lines represent the week of positive RT-PCR test result(s), and shaded areas indicate weeks with consecutive positive RT-PCR test results. Colors show disease severity during acute infection. Dotted horizontal lines indicate the limit of detection for the SARS-CoV-2 IgG assay (1.40).

Figure 5. Change in nucleocapsid-binding antibody levels longitudinally in children and adults.

A) Aggregated index values for children without immunocompromising conditions over one-year post-symptom onset with lines connecting specimens from the same individual. **B)**

Comparison of index values between pediatric and adult cohorts restricted to the same time periods of collection. C) Change in index values at 24 to 29 weeks relative to specimens collected at 8 to 13 weeks for children and adults with specimens collected within both timeframes. Significance determined by Mann Whitney test. Dotted lines indicate the limit of detection for the SARS-CoV-2 IgG assay (1.40).

Supplemental figures:

Supplemental Table 1. Evidence of SARS-CoV-2 infection among patients without a confirmed SARS-CoV-2 RT-PCR.

Patient ID	Evidence of SARS-CoV-2 infection	Epi-week of household RT-PCR test	Epi-week of participant symptom onset
C15	Experienced symptomatic infection, developed MIS-C, neutralization and nucleocapsid antibodies confirmed through serological testing; this child is listed on the MIS-C subset in inclusion flowchart.	not applicable	2020 week 11 - acute 2020 week 18 - MIS-C
C12	Known PCR-positive household infection (family member with long COVID who was not tested until well after initial household outbreak), entire family experienced symptoms consistent with SARS-CoV-2 infection, neutralization and nucleocapsid antibodies confirmed through serological testing	2020 week 20	2020 week 11
C20	Known PCR-positive household infection, experienced symptoms consistent with SARS-CoV-2 infection, neutralization and nucleocapsid antibodies confirmed through serological testing	unknown	2020 week 12
C23	Known PCR-positive household infection, experienced symptoms consistent with SARS-CoV-2 infection, neutralization and nucleocapsid antibodies confirmed through serological testing	two family members positive both in 2020 week 49	2020 week 49
C14	Known PCR-positive contacts, experienced symptoms consistent with SARS-CoV-2 infection, neutralization and nucleocapsid antibodies confirmed through serological testing	2020 week 48	2020 week 48

Supplemental figure 1. Distribution of specimen collections in children and adults.

Supplemental figure 2. Neutralization titers in adults over time. A) Neutralizing antibody titers in 14 adults with confirmed SARS-CoV-2 infection followed prospectively over time shown as weeks post-symptom onset, x axis. **B)** Aggregated neutralization titers for all adults. Dotted horizontal lines indicate the limit of detection (20).

A

B

Supplemental figure 3. Nucleocapsid-binding antibody levels in adults over time. A) The SARS-CoV-2 IgG assay was used to determine SARS-CoV-2 nucleocapsid-binding antibody in 14 adults followed prospectively over time shown as weeks post-symptom onset, x axis. **B)** Aggregated index values for all adults. Dotted horizontal lines indicate the limit of detection for the SARS-CoV-2 IgG assay (1.40).

Supplemental Table 2. Naming of adults across publications.

Naming in Crawford et al. 2020 (3)	Naming in the present study
------------------------------------	-----------------------------

PID 13	A3
PID 3C	A1
PID 4C	A2
PID 6C	A6
PID 7C	A7
PID 11C	A4
PID 12C	A10
PID 22C	A9
PID 23C	A8
PID 24C	A13
PID 103C	A12
PID 113C	A14
PID 117C	A11
PID 200C	A5